The use of tranexamic acid (TXA) has markedly increased since the results of the CRASH-II trial were published. In addition to its use in trauma, TXA has been evaluated and used in numerous other conditions, including post-partum hemorrhage and epistaxis. Recently, the HALT-IT Trial was published online in the Lancet, which evaluated the use of TXA in patients with acute gastrointestinal bleeding. In this podcast we discuss the HALT-IT Trial and its implications for clinical practice.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
In recent years, the use of e-cigarette and vaping products has sharply risen. Concomitant with the increased use is an increase in patients presenting...
More than 350,000 cardiac arrests occur each year in North America. Approximately 100,000 of these arrests are due to shockable rhythms. Unfortunately, many patients...
As bitter cold temperatures grip the Northeast, many struggle to stay warm and often resort to nontraditional methods of heating. As a result, there...
